Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions
AssigneeMitotech SA
InventorsMaxim V. SKULACHEV, Roman ZINOVKIN, Alexander ANDREEV-ANDRIEVSKY, Maxim EGOROV, Elena KARGER, Anton PETROV, Lawrence FRIEDHOFF
Life of this patent
Estimating the term…
Abstract
Mitochondrially targeted antioxidants are used to prevent and treat severe inflammatory conditions including viral infection (such as COVID-19), systemic shock, trauma, burns, surgery associated with significant tissue damage, toxic damage, and damage associated with autoimmune reactions.
Claims17
A method to aid in treating or preventing an inflammatory condition in a subject in need thereof, the method comprising administration of a mitochondrially-targeted antioxidant of formula I (SkQ)
- wherein A is an effector moiety/antioxidant optionally having the following structure:
- and/or a reduced form thereof, wherein m is an integer from 1 to 3;
- each Y is independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, or two adjacent Y groups, together with carbon atoms to which they are attached, forming the following structure:
- and/or a reduced form thereof, wherein R1 and R2 may be the same or different and are each independently C1-6 alkyl or C1-6 alkoxy;
- wherein L is a linker group, comprising:
- a) straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds;
- and/or
- b) a natural isoprene chain;
- wherein n is integer from 1 to 40;
- wherein B is a mitochondria-targeting group comprising a lipophilic cation and a pharmacologically acceptable anion;
- and/or solvates, salts, isomers, or prodrugs thereof.
The method of any of the preceding claims, wherein the inflammatory condition is associated with infection, COVID-19, sepsis or septic shock, cytokine storm or SIRS, vascular endothelial damage, activation of vascular endothelial cells, PAMPS, DAMPS, cold shock, heat shock, toxic shock, burn trauma, surgery, autoimmune disease, anaphylaxis, cancer, ischemic disease, or presence of CIRP and/or HMGB1 in the blood of the subject.
The method of any of the preceding claims, wherein SkQ is administered by intravenous injection or infusion, subcutaneous injection, or a slow release formulation or device.
The method of any of the preceding claims, wherein the method prevents deconstruction of cell-to-cell contacts between endothelial cells of the subject.
The method of any of the preceding claims, further comprising administering an additional therapeutic agent.
The method of any of the preceding claims, wherein the method prevents the subject from contracting COVID-19.
A kit comprising mitochondrially-targeted antioxidant SkQ of formula I below and instructions for performing the method of any of the preceding claims:
- wherein A is an effector moiety/antioxidant optionally having the following structure:
- and/or a reduced form thereof, wherein m is an integer from 1 to 3;
- each Y is independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, or two adjacent Y groups, together with carbon atoms to which they are attached, forming the following structure:
- and/or a reduced form thereof, wherein R1 and R2 may be the same or different and are each independently C1-6 alkyl or C1-6 alkoxy;
- wherein L is a linker group, comprising:
- a) straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds;
- and/or
- b) a natural isoprene chain;
- wherein n is integer from 1 to 40;
- wherein B is a mitochondria-targeting group comprising a lipophilic cation and a pharmacologically acceptable anion;
- and/or solvates, salts, isomers, or prodrugs thereof.
A composition for use in treating or preventing an inflammatory condition in a subject in need thereof, the composition comprising a mitochondrially-targeted antioxidant of formula I (SkQ)
- wherein A is an effector moiety/antioxidant optionally having the following structure:
- and/or a reduced form thereof, wherein m is an integer from 1 to 3;
- each Y is independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, or two adjacent Y groups, together with carbon atoms to which they are attached, forming the following structure:
- and/or a reduced form thereof, wherein R1 and R2 may be the same or different and are each independently C1-6 alkyl or C1-6 alkoxy;
- wherein L is a linker group, comprising:
- a) straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds;
- and/or
- b) a natural isoprene chain;
- wherein n is integer from 1 to 40;
- wherein B is a mitochondria-targeting group comprising a lipophilic cation and a pharmacologically acceptable anion;
- and/or solvates, salts, isomers, or prodrugs thereof.
Dependencies are inferred from the claim text.